Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study

Authors: Di Pietro, F.R. ^{∗, 1}, Verkhovskaia, S. ^{∗, 1}, Mastroeni, S. ^†, Carbone, M.L. ^‡, Abeni, D. ^†, Di Rocco, C.Z. ^∗, Samà, N. ^∗, Zappalà, A.R. ^∗, Marchetti, P. ^{§, ||}, De Galitiis, F. ^∗, Failla, C.M. ^‡, Fortes, C. ^†

Source: In Clinical Oncology January 2022 34(1):e18-e24

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Authors: Maio, M. ^*, Danielli, R., Chiarion-Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., De Rosa, F., Del Vecchio, M., Di Guardo, L., Queirolo, P., Picasso, V., Marchetti, P., De Galitiis, F., Mandalà, M., Guida, M., Simeone, E., Ascierto, P.A.

Source: In Annals of Oncology November 2013 24(11):2911-2915

1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716

Authors: Luke, J.J., Ascierto, P.A., Khattak, M.A., Rutkowski, P., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Cruz Merino, L. de la, Chiarion Sileni, V., Kirkwood, J.M., Robert, C., Schadendorf, D., De Galitiis, F., Carlino, M.S., Odeleye-Ajakaye, A., Kalabis, M., Krepler, C., Eggermont, A.M.M., Long, G.V.

Source: In Annals of Oncology September 2024 35 Supplement 2:S715-S715

Survie sans métastases à distance avec pembrolizumab versus placebo en traitement adjuvant du mélanome de stade IIB ou IIC : étude de phase III KEYNOTE-716

Authors: Grob, J.J., Long, G., Luke, J., Khattac, A., Merino, L. De La Cruz, Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J.M., Robert, C., De Galitiis, F., Schadendorf, D., Carlino, M.S., Wu, X.L., Kalabis, M., Krepler, C., Eggermont, A., Ascierto, P.A.

Source: In Annales de Dermatologie et de Vénéréologie - FMC November 2022 2(8) Supplement 1:A128-A128

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Authors: Luke, J.J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion Sileni, V., de la Cruz Merino, L., Khattak, M.A., Schadendorf, D., Long, G.V., Ascierto, P.A., Mandala, M., De Galitiis, F., Sondak, V., Scolyer, R.A., Kirkwood, J.M., Chen, K., Ibrahim, N., Ahsan, S., Eggermont, A.M.M.

Source: In Annals of Oncology September 2021 32 Supplement 5:S1314-S1315

1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile

Authors: Del Vecchio, M., Di Giacomo, A.M., Quaglino, P., Chiarion Sileni, V., Queirolo, P., De Galitiis, F., Cognetti, F., Mandala', M., Guidoboni, M., Rinaldi, G., Depenni, R., Consoli, F., Troiani, T., Guida, M., Marconcini, R., Ferrucci, P.F., Bersanelli, M., E. rossi, Aglietta, M., Ascierto, P.A.

Source: In Annals of Oncology September 2021 32 Supplement 5:S890-S891

55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

Authors: Nigro, O., Cortellini, A., Giusti, R., Marchetti, P., De Galitiis, F., Di Pietro, F.R., Bersanelli, M., Lazzarin, A., Galetta, D., Pizzutillo, P., Santini, D., Torniai, M., De Giglio, A., Russo, A., Silva, R.R., Bolzacchini, E., Natoli, C., Rijavec, E., Vallini, I., Pinotti, G.

Source: In Annals of Oncology December 2019 30 Supplement 11:xi20-xi20

This result is not displayed to guests.
Login for full access.

1228P - Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy

Authors: Bidoli, P., Chiari, R., Catino, A., Grossi, F., Noberasco, C., Gelsomino, F., Gilli, M., Proto, C., Parra, H.J. Soto, Migliorino, M.R., Bonomi, L., Tassinari, D., Frassoldati, A., Albanese, V., Fadda, G.M., Cognetti, F., de galitiis, F., Finocchiaro, G., Delmonte, A.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi425-vi425

1225P - Preliminary efficacy and safety data of nivolumab in never smoker patients with advanced squamous NSCLC: Experience from Italian sites participating in the Expanded Access Programme (EAP)

Authors: Vitali, M., Crinò, L., Logroscino, A.F., Ardizzoni, A., Caponnetto, S., Landi, L., Bordi, P., Luana, C., Barbieri, F., Santo, A., Santarpia, M., Carteni, G., Mini, E., Vasile, E., Morgillo, F., De Galitiis, F., Conca, R., Macerelli, M., Tedde, N., Vitiello, F.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi424-vi424

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

1132P - Efficacy and Safety Data from Patients with Advanced Melanoma and Brain Metastases Participating in the European Ipilimumab Expanded Access Programme (EAP) in Italy

Authors: Queirolo, P., Simeone, E., De Galitiis, F., Di Guardo, L., Di Giacomo, A.M., Marconcini, R., Ferraresi, V., De Rosa, F., Guida, M., Stragliotto, S.

Source: In Annals of Oncology September 2012 23 Supplement 9:ix369-ix369

1128P - The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma

Authors: Ascierto, P.A., Sileni, V. Chiarion, Del Vecchio, M., Altomonte, M., De Galitiis, F., Ridolfi, L., Cognetti, F., Testori, A., Bernengo, M.G., Queirolo, P.

Source: In Annals of Oncology September 2012 23 Supplement 9:ix367-ix368

1133P - Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP)

Authors: Maio, M., Sileni, V. Chairion, Pilla, L., Nicoletti, S.V.L., Di Guardo, L., Queirolo, P., De Galitiis, F., Mandala, M., Guida, M., Ascierto, P.A.

Source: In Annals of Oncology September 2012 23 Supplement 9:ix369-ix370

1130P - Efficacy and Safety of Ipilimumab in Patients with Pretreated, Mucosal Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP)

Authors: Del Vecchio, M., Simeone, E., Sileni, V. Chiarion, Nuzzo, C., Rinaldi, G., Testori, A., De Galitiis, F., Queirolo, P., Marconcini, R., Maio, M.

Source: In Annals of Oncology September 2012 23 Supplement 9:ix368-ix368